Prioritize viral vectors, oncology and rare disease therapies, with North America offering strong ROI potential through regulatory support, R&D investment and early adoptionDublin, Oct. 08, 2026 ...

Record global approvals, CRISPR breakthroughs, and expanding clinical and commercial activity are accelerating demand for cell and gene therapy tools and reagents.Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE ...

Explore advancements in disease detection using artificial intelligence to diagnose rare genetic disorders in children faster ...

A new Pediatric Research commentary argues that insurance coverage and reimbursement policy, not the underlying science, now ...

Ultragenyx Pharmaceutical RARE has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review ...

A $25 million gift from the Smilow Foundation, led by William Smilow, will establish the Smilow Center for Precision ...

What you'll discover in this article ・A phase 1 trial of optogenetic therapy to partially restore sight in patients with a genetic form of blindness has shown the technique is safe and promising. ・The ...

His travel history and clinical presentation led health officials to treat the case as a suspected Ebola infection and follow ...

New model enables researchers to explore how Hutchinson-Gilford Progeria Syndrome affects three layers of cells in blood ...

Spread the love“`html Imagine a future where your doctor doesn’t just treat your symptoms, but understands the very blueprint ...

A new review in the Journal of Translational Medicine proposes a four-layer functional integration framework that combines ...

The preparations are part of the Government’s national contingency plan and will cover Kenya’s coastline, lakes and shared ...